MYNZ
Mainz Biomed NV
NASDAQ · Healthcare · Medical - Diagnostics & Research · DE
$3.59
+0.84%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.5%
- EBITDA
- +17.5%
- EBIT
- +13.7%
- Net income
- +25.1%
- EPS
- +87.9%
- Free cash flow
- +36.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025